Roche rejigs UK comms for cancer drug portfolio

Roche is to shake up UK product comms within its weighty cancer drug portfolio. An agency pitch for MabThera is on the cards and the firm has brought in fresh backing for Avastin.

by Ian Hall

Sign in to continue

Sign in

Sign in

Trouble signing in?

Reset password: Click here

US and Asia
subscriptions@prweek.com
+001 (800) 558-1708

UK & Europe
support@prweek.com
+44 (0)20 8267 8121

Register

Don't have an account? Complete easy registration and receive:

Limited Article Views (Excludes Subscriber Only Content)
Select Newsletters (Excludes Subscriber Only Bulletins)

Register

FREE

Limited free articles a month
Limited number of free email bulletins

Subscribe to The Knowledge

To receive full access to PRWeek's content subscribe today and receive:

Unrestricted access to all The Information and The Knowledge content
Access to the new PRWeek Data Hub
Exclusive access to in-depth reports including the Top 150 UK PR Consultancies Report, Industry Awards Rankings, Industry Salaries Report, and more

Subscribe

To receive full access to PRWeek's content subscribe today and receive:

Unrestricted individual access to prweek.com
Breaking news and industry updates via PRWeek Daily News bulletin
Exclusive access to Agency Business Report, annual Salary Survey, Power List, 40 Under 40, & Best Places to Work, and more

Subscribe Options

Start your free trial

Join today and get:

Unrestricted individual access to prweek.com
Breaking news and industry updates via PRWeek Daily News bulletin
Exclusive access to Power Book and Top 150 UK Agency Business Report

Need to activate your subscription?

Domain/Group Subscriptions
Click here >>

Individual Subscriptions
Click here >>

Need to activate your Subscription

Company Wide Subscriptions
Click here >>

UK Individual Subscribers
Click here >>

Recommended for you

Recommended for you

Explore further